Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) Director Redmile Group, Llc acquired 133,371 shares of Shattuck Labs stock in a transaction dated Wednesday, December 4th. The shares were bought at an average cost of $1.25 per share, for a total transaction of $166,713.75. Following the completion of the purchase, the director now directly owns 5,539,724 shares of the company's stock, valued at approximately $6,924,655. The trade was a 2.47 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shattuck Labs Trading Down 4.6 %
NASDAQ STTK opened at $1.25 on Friday. The stock has a 50-day moving average of $1.36 and a 200 day moving average of $3.42. Shattuck Labs, Inc. has a one year low of $0.94 and a one year high of $11.76.
Analysts Set New Price Targets
A number of equities research analysts recently commented on STTK shares. Citigroup lowered shares of Shattuck Labs from a "buy" rating to a "neutral" rating and lowered their price target for the company from $8.00 to $2.00 in a report on Wednesday, October 2nd. HC Wainwright reaffirmed a "neutral" rating on shares of Shattuck Labs in a research note on Friday, November 15th. Evercore ISI raised shares of Shattuck Labs to a "strong-buy" rating in a research report on Wednesday, October 2nd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Shattuck Labs in a research note on Thursday, November 14th. Four investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Shattuck Labs has an average rating of "Hold" and a consensus target price of $8.67.
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings | Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.
View Our Latest Analysis on Shattuck Labs
Hedge Funds Weigh In On Shattuck Labs
Several hedge funds and other institutional investors have recently modified their holdings of STTK. Barclays PLC increased its stake in shares of Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company's stock worth $189,000 after purchasing an additional 40,717 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Shattuck Labs by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company's stock valued at $3,184,000 after acquiring an additional 8,133 shares during the period. EP Wealth Advisors LLC purchased a new stake in Shattuck Labs in the 3rd quarter worth approximately $144,000. State Street Corp raised its stake in Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company's stock worth $2,675,000 after acquiring an additional 55,579 shares during the period. Finally, Readystate Asset Management LP purchased a new position in Shattuck Labs during the third quarter valued at approximately $39,000. 58.74% of the stock is owned by institutional investors.
Shattuck Labs Company Profile
(
Get Free Report)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
